Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Research in Cardiology
Published in: Clinical Research in Cardiology 4/2008

01-04-2008 | ORIGINAL PAPER

Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy

Authors: F. Peters-Klimm, MD, T. Müller-Tasch, MD, D. Schellberg, PhD, A. Remppis, MD, A. Barth, N. Holzapfel, MA, J. Jünger, MD, W. Herzog, MD, J. Szecsenyi, MD, MSc

Published in: Clinical Research in Cardiology | Issue 4/2008

Login to get access

Abstract

Background

There is robust evidence for effective pharmacotherapy of chronic (systolic) heart failure (CHF) which has led to the creation of guidelines, but many surveys evaluating CHF treatment show an under-utilisation of relevant drugs, while setting and patient population appear to be crucial for adequate appraisal of treatment patterns.

Aims

To evaluate the guideline adherence (GA) of general practitioners (GPs) in a well-defined patient population with CHF in primary care (PC).

Methods

A cross-sectional analysis was performed with the data of 167 patients enrolled in 37 GP practices (Germany) with documented left ventricular systolic dysfunction (LVEF: 33.3 ± 6.9%). GA was assessed as usual (prescribing “yes” or “no”), through evaluation of target dosing, while adjusting for potential clinical contraindications, and through a modified Guideline Adherence Indicator-3 (mGAI-3), which assesses three relevant groups of substances according to New York Heart Association (NYHA) functional class: ACE-Inhibitors (ACE-I) or angiotensin receptor blockers (ARB), beta-blockers (BB) and aldosterone-antagonists (AA).

Results

Prescription rates for ACE-I/ARB, BB or both were 80%, 75% and 62%, respectively. The proportion of target doses reached for ACE-I was 16%, for BB only 8%. When adjusted for potential (mainly relative) contraindications (COPD, heart rate <60/min, hypotension, hyperkalaemia and renal dysfunction), the percentage of target doses reached increased to 49% for ACE-I/ARBs and 46% for BB. Application of the mGAI-3 showed moderate to perfect GA for usual assessment, proportion of target dose reached and adjusted in 83%, 16% and 55% of the patients, respectively.

Conclusion

In the context of this patient and doctor setting, life-saving treatment was provided above average when assessed by usual criteria. The application of additional criteria showed further room for improvement. Future interventions aiming at optimisation should be tailored to the needs of doctors and patients likewise.
Literature
1.
A fifth amendment for the declaration of Helsinki (2000) Lancet 356(9236): 1123
2.
Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. (2006) Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355(3):260–269PubMedCrossRef
3.
Bongers FJ, Schellevis FG, Bakx C, van den Bosch WJ, van der Zee J (2006) Treatment of heart failure in Dutch general practice. BMC Fam Pract 7:40PubMedCrossRef
4.
Bouvy ML, Heerdink ER, Leufkens HG, Hoes AW (2003) Predicting mortality in patients with heart failure: a pragmatic approach. Heart 89(6):605–609PubMedCrossRef
5.
Cleland JG, Cohen-Solal A, Aguilar JC, Dietz R, Eastaugh J, Follath F, et al. (2002) Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 360(9346): 1631–1639PubMedCrossRef
6.
Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. (2003) The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 24(5):442–463PubMedCrossRef
7.
Drechsler K, Dietz R, Klein H, Wollert KC, Storp D, Molling J, et al. (2005) Euro heart failure survey. Medical treatment not in line with current guidelines. Z Kardiol 94(8):510–515PubMedCrossRef
8.
Freeman AC, Sweeney K (2001) Why general practitioners do not implement evidence: qualitative study. BMJ 323(7321):1100–1102PubMedCrossRef
9.
Friedrich EB, Teo KK, Bohm M (2006) ACE inhibition in secondary prevention: are the results controversial? Clin Res Cardiol 95(2):61–67PubMedCrossRef
10.
Hoppe UC, Bohm M, Dietz R, Hanrath P, Kroemer HK, Osterspey A, et al. (2005) Guidelines for therapy of chronic heart failure. Z Kardiol 94(8):488–509PubMedCrossRef
11.
Hoppe UC, Erdmann E (2001) Guidelines for the treatment of chronic heart failure. Issued by the Executive Committee of the German Society of Cardiology-Heart and Circulation Research, compiled on behalf of the Commission of Clinical Cardiology in cooperation with Pharmaceutic Commission of the German Physicians’ Association. Z Kardiol 90(3):218–237PubMedCrossRef
12.
Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W, et al. (2002) Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 87(3):235–241PubMedCrossRef
13.
Julian DG (2004) Translation of clinical trials into clinical practice. J Intern Med 255(3):309–316PubMedCrossRef
14.
Khunti K, Hearnshaw H, Baker R, Grimshaw G (2002) Heart failure in primary care: qualitative study of current management and perceived obstacles to evidence-based diagnosis and management by general practitioners. Eur J Heart Fail 4(6):771–777PubMedCrossRef
15.
Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, et al. (2003) The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 24(5):464–474PubMedCrossRef
16.
Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, Erdmann E, et al. (2005) Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 26(16):1653–1659PubMedCrossRef
17.
Lainscak M, Cleland JG, Lenzen MJ, Follath F, Komajda M, Swedberg K (2007) International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: Data from the EuroHeart Failure Survey. Eur J Heart Fail 9(3):292–299PubMedCrossRef
18.
Lenzen MJ, Boersma E, Scholte op Reimer WJM, Balk AHMM, Komajda M, Swedberg K, et al. (2005) Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J 26(24):2706–2713PubMedCrossRef
19.
Luke DR, Halstenson CE, Opsahl JA, Matzke GR (1990) Validity of creatinine clearance estimates in the assessment of renal function. Clin Pharmacol Ther 48(5):503–508PubMedCrossRef
20.
Muntwyler J, Cohen-Solal A, Freemantle N, Eastaugh J, Cleland JG, Follath F (2004) Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe. Eur J Heart Fail 6(5):663–668PubMedCrossRef
21.
O’Connell JB (2000) The economic burden of heart failure. Clin Cardiol 23(3 Suppl):6–10
22.
Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355(3):251–259PubMedCrossRef
23.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709–717PubMedCrossRef
24.
Reibis R, Dovifat C, Dissmann R, Ehrlich B, Schulz S, Stolze K, et al. (2006) Implementation of evidence-based therapy in patients with systolic heart failure from 1998–2000. Clin Res Cardiol 95(3):154–161PubMedCrossRef
25.
Remme WJ, Swedberg K (2002) Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail 4(1):11–22PubMedCrossRef
26.
Rickham PP (1964) Human experimentation. Code of ethics of the world medical association. Declaration of helsinki. Br Med J 2(5402):177PubMedCrossRef
27.
Rutten FH, Grobbee DE, Hoes AW (2003) Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice. Eur J Heart Fail 5(3):337–344PubMedCrossRef
28.
Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, et al. (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41(9):1529–1538PubMedCrossRef
29.
Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. (2006) A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333(7557):15PubMedCrossRef
30.
Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ (2001) More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 3(3):315–322PubMedCrossRef
31.
Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. (2005) Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur Heart J 26(11):1115–1140PubMedCrossRef
32.
The Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342(3):145–153CrossRef
33.
Wikstrand J, Hjalmarson A, Waagstein F, Fagerberg B, Goldstein S, Kjekshus J, et al. (2002) Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 40(3):491–498PubMedCrossRef
Metadata
Title
Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy
Authors
F. Peters-Klimm, MD
T. Müller-Tasch, MD
D. Schellberg, PhD
A. Remppis, MD
A. Barth
N. Holzapfel, MA
J. Jünger, MD
W. Herzog, MD
J. Szecsenyi, MD, MSc
Publication date
01-04-2008
Publisher
D. Steinkopff-Verlag
Published in
Clinical Research in Cardiology / Issue 4/2008
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-007-0617-6

Other articles of this Issue 4/2008

Clinical Research in Cardiology 4/2008 Go to the issue

ORIGINAL PAPER

Low HDL levels and the risk of death, sepsis and malignancy

CLINICAL CORRESPONDENCE

Left circumflex coronary artery fistula to the superior vena cava: assessment of the exact anatomy by multidetector CT

ORIGINAL PAPER

Sirolimus-eluting stents in the treatment of chronic total coronary occlusions

CLINICAL CORRESPONDENCE

Cardiac magnetic resonance imaging: an essential diagnostic aid in suspected myocardial re-infarction in a 40 year old woman

CLINICAL CORRESPONDENCE

Delayed enhancement magnetic resonance imaging in isolated noncompaction of ventricular myocardium

ORIGINAL PAPER

Evaluation of the dedicated Frontier™ coronary bifurcation stent: A matched pair analysis with drug-eluting and bare metal stents